# A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

> **NCT02317419** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 15 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** RO6927005
- **DRUG:** RO6927005
- **DRUG:** gemcitabine
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT02317419
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The study was prematurely terminated because the emerging benefit:risk ratio did not justify continuing dosing patients.
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02317419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02317419, "A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02317419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*